Key result
Valsartan alone or combined with enalapril at non-hypotensive doses improved survival compared to untreated animals or enalapril alone in spontaneously hypertensive rats.
Why the study?
Does valsartan alone or in combination with enalapril improve survival in spontaneously hypertensive rats with endothelial dysfunction?
Does valsartan alone or in combination with enalapril improve survival in spontaneously hypertensive rats with endothelial dysfunction?
In a rat model of endothelial dysfunction, non-hypotensive doses of valsartan, alone or with enalapril, improved survival despite no improvement in histological appearance or kidney function.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; hypothesis-generating for non-hypotensive ARB or ARB-ACEI regimens in hypertensive models.
There is increasing evidence to suggest endothelial dysfunction as a critical factor in vascular diseases. Genetically predisposed spontaneously hypertensive rats (SHR) treated with inhibitors of nitric oxide (NO) synthase, develop a severe hypertensive nephrosclerosis without the necessity for surgical reduction in renal mass, nephrectomy, renal infarction or nephrotoxic drugs. In these animals, endothelial dysfunction is considered a valid model for assessment of the efficacy of cardiovascular therapy. SHR were treated with either the angiotensin-converting enzyme inhibitor enalapril or the angiotensin II (Ang II) AT(1)-receptor antagonist (AIIA) valsartan at sub-hypotensive doses and the effects on survival rates, cardiac and renal changes were monitored. Rats treated with valsartan, alone or in combination with enalapril, showed markedly higher survival rates (67-85%, respectively) than untreated animals (37%) or those treated with enalapril alone (55%). Valsartan at a dose which attenuated blood pressure increase led to even greater survival rates (95%). Despite these improved survival rates, at non-hypotensive doses the drugs had no effect on histological appearance, nor was kidney function improved. Plasma creatinine levels were reduced by valsartan, alone or in combination with enalapril, but proteinuria persisted with all treatments over the 12 weeks of the study. Aldosterone levels were significantly reduced by all treatments. The results suggest a beneficial role for endothelium in hypertension. Reduced renal perfusion pressure probably underlies the beneficial renal effects of high-dose valsartan.
No takes yet. Share an insight, caveat, or question.
Gasparo et al. (2000) studied Hypertension with endothelial dysfunction. Valsartan alone or in combination with enalapril vs. Untreated animals or enalapril alone was evaluated on Survival rates. Valsartan alone or combined with enalapril at non-hypotensive doses improved survival compared to untreated animals or enalapril alone in spontaneously hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: